Monday, February 26, 2024
Allyx Therapeutics was founded in 2019 by a group of seasoned biopharma industry executives, venture capitalists, and scientific experts. The company aims to deliver a novel approach to preserve and protect synapses for people living with neurodegenerative diseases. Its lead compound, ALX-001 is a first-in-class oral therapy with a unique mechanism of action at mGluR5 currently in clinical development in Alzheimer’s disease and Parkinson's disease.
CEO/Top Company Official
Stephen Bloch, MD
Lead Product in Development
ALX-001 is a novel first-in-class silent allosteric modulator of mGluR5 which acts selectively to block the toxicity of soluble misfolded protein aggregates on neuronal synapses. The drug is orally bioavailable with confirmed target engagement in the human brain.
Development Phase of Primary Product